

Receipt date: 11/23/2010

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/771,440
				Filing Date	February 05, 2004
				First Named Inventor	DANIELY Michal et al
				Group Art Unit	1643
				Examiner Name	DUFFY Bradley
Sheet	1	Of	2	Attorney Docket Number 26003	
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	1	Supplementary European Search Report Dated 01 August 2007 From the European Patent Office Re.: Application No. 04725136.8.			
	2	Kaplinsky et al. "Combined Analysis of Morphology and FISH Using the Duet™ Automatic Cells Scanning System, Increases the Accuracy of Leukemia Diagnosis", The Hematology Journal, 3: 201, Poster No.0668, 2002. Abstract.			
	3	Kaplinsky et al. "Increased Accuracy of Leukemia Diagnosis by Combined Analysis of Morphology and FISH Using the Duet™ Automatic Cell Scanning System", European Journal of Human Genetics, 10(Suppl. 1): 90, 2002. &European Human Genetics Conference 2002 in Conjunction With the European Meeting on Psychological ASP, Strasbourg, France, 2002.			
	4	Knudson et al. "Comparison of the BioView™ Duet Automated Dot Counting System to Technologist Scoring Using the D-FISH Strategy in Patients With CML", Association of Genetic Technologists Annual Meeting, 5-8 June 2003, Atlanta, GA, USA, 1 P., 2003. Abstract.			
	5	Malingier et al. "Automatic Scanning of Interphase FISH for Prenatal Diagnosis in Uncultured Amniocytes", Annales de Génétiques, International Journal of Human and Medical Genetics, 46(13.27): 323, 2003. Abstract.			
	6	Rosenberg et al. "Major Mutations in Calf-1 and Calf-2 Domains of Glycoprotein IIb in Patients With Glanzmann Thrombasthenia Enable GPIIb/IIIa Complex Formation, But Impair Its Transport From the Endoplasmic Reticulum to the Golgi Apparatus", Blood, 101(12): 4808- 4816, 2003.			
	7	Rothman et al. "A New AML1 Deletion in Pediatric TEL/AML1 Positive ALL Patients: Detection and Monitoring of Minimal Residual Disease by FISH Analysis", 38th Annual Congress of the Israeli Society for Clinical Laboratory Sciences, Tel Aviv, IL, 2004. Abstract.			
	8	Rothman et al. "Additional Cytogenetic Events in Pediatric Acute Lymphoblastic Leukemia Patients With T(12:12): Deletion of the Region 3' to the AML1 Breakpoint (Intron 2) and Subsequent Deletion of the Normal TEL Allele", Annales de Génétiques, International Journal of Human and Medical Genetics, 46(2.68): 139, 2003. Abstract.			
	9	Shimoni et al. "Chimerism Testing and Detection of Minimal Residual Disease After Allogeneic Hematopoietic Transplantation Using the BioView (Duet) Combines Morphological and Cytogenetical Analysis", Leukemia, 16: 1413-1418, 2002.			
Examiner Signature	Brad Duffy/			Date Considered	06/28/2011

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Receipt date: 11/23/2010

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

~~(use as many sheets as necessary)~~

Complete if Known

Application Number	10/771,440
Filing Date	5/2/2004
First Named Inventor	DANIELY Michal et al
Art Unit	1643
Examiner Name	DUFFY Bradley

Sheet	2	Of	2	Attorney Docket Number	26003
-------	---	----	---	------------------------	-------

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.
-----------------------	--------------------------	---

 T^2

10	Skacel et al. "Validation of A Multicolor Interphase Fluorescence In Situ Hybridization Assay for Detection of Transitional Cell Carcinoma on Fresh and Archival Thin-Layer, Liquid-Based Cytology Slides", Analytical and Quantitative Cytology and Histology, 23(6): 381-387, 2001.
----	---

11	Trakhtenbrot et al. "Clinical Significance of the Combined Morphological, Immunophenotypic and Molecular Cytogenetic Analysis of Hematological Malignancies". Annales de Génétique, International Journal of Human and Medical Genetics, 46(2.80): 145, 2003. Abstract.
----	---

Examiner Signature	/Brad Duffy/	Date Considered	06/28/2011
-----------------------	--------------	--------------------	------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicants to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14, this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.